

1 CHAMP study team contributors: Ed Acosta<sup>a</sup>, Sara Gianella<sup>b</sup>, Davey Smith<sup>b</sup>, Ronald Mitsuyasu<sup>c</sup>

2

3 <sup>a</sup>University of Alabama, Birmingham at Birmingham, AL; <sup>b</sup>University of California, San Diego, San  
4 Diego, CA; <sup>c</sup>University of California, Los Angeles, Los Angeles, CA.

5

6

7

7 **Supplemental Tables**  
8

PTC Definition	pVL limit	% Time Points	Weeks Post-ATI
CHAMP	400 cps/mL	≥2/3	≥24
90%		90%	
100%		100%	
200 cps/mL	200 cps/mL		
1,000 cps/mL	1,000 cps/mL		
48 weeks			≥48

9  
10 **Supplemental Table 1. Alternative post-treatment controller definitions.** This table depicts the  
11 criteria for alternative post-treatment controller (PTC) definitions. Blanks in the table denote  
12 criteria concordant with the CHAMP definition (≥2/3 of timepoints must have a VL ≤400 cps/mL  
13 for at least 24 weeks). pVL, plasma viral load; cps, copies.



251658240

PTC Definition	Pre-ART VL (log <sub>10</sub> HIV-1 RNA copies/mL)				CD4+ Decline (cells/mm <sup>3</sup> )				Baseline CD4+ Count (cells/mm <sup>3</sup> )				Peak VL (log <sub>10</sub> HIV-1 RNA copies/mL)				PTC
	PTC	NC	Difference	p-value	PTC	NC	Difference	p-value	PTC	NC	Difference	p-value	PTC	NC	Difference	p-value	
CHAMP	4.57	5.25	-0.68	<0.01	-31.7	-208.7	177	<0.001	882	825	57	0.7	2.89	4.74	-2.05	<0.001	8
90%	4.61	5.24	-0.63	0.05	1.5	-205.4	206.9	<0.001	884	826	58	0.8	1.97	4.72	-2.75	<0.001	8
100%	4.72	5.24	-0.52	0.08	3.7	-204.9	208.6	<0.001	891	825	66	0.3	1.88	4.71	-2.84	<0.001	10
200 cps/mL	4.72	5.24	-0.52	<0.05	-0.6	-206.3	205.7	<0.001	882	825	57	0.8	2.33	4.73	-2.4	<0.001	8
1,000 cps/mL	4.74	5.28	-0.52	<0.05	-87.6	-221.7	154.1	<0.001	889	824	35	0.7	3.24	4.77	-1.53	<0.001	8
48 weeks	4.52	5.24	-0.72	0.08	-53.5	-205.9	152.4	<0.001	922	825	97	0.1	2.47	4.73	-2.25	<0.001	9

**Supplemental Table 2. Differences in PTC cohort characteristics based on definition of post-treatment**

**control.** “CHAMP” refers to the PTC criteria used in the CHAMP study: pVL<400 cps/mL at ≥2/3 time points for ≥24 weeks post-ATI. “100%” criteria = pVL<400 cps/mL at 100% of time points for ≥24 weeks post-ATI. “90%” criteria = pVL<400 cps/mL at 90% of time points for ≥24 weeks post-ATI. “200 cps/mL” criteria = pVL<200 cps/mL at ≥2/3 of time points for ≥24 weeks post-ATI. “1,000 cps/mL” criteria = pVL<1,000 cps/mL at ≥2/3 of time points for ≥24 weeks post-ATI. “48 weeks” criteria = pVL<200 cps/mL at ≥2/3 of time points for ≥48 weeks post-ATI. NC, post-treatment non-controllers who did not meet each of the different PTC criteria. P-values were calculated using a Mann-Whitney test; Peak VL, highest HIV-1 viral load during the first 24 weeks of treatment interruption.

251658240

Week Participant	1	2	3	4	5	6	7	8	9	10	
1	100	150	150	200	100	200	300	600	400	500	
2	1,000		2,000		100		5,000		400	800	
3	5,000				10,000			3,000			
4	400	3,000		15,000		300			12,000	2,000	

**Supplemental Table 3. Mock 12 week data set.** This mock data set depicts 4 participants with heterogeneity in plasma viral load (pVL) testing during the first 12 weeks of ATI. The pVL restart criteria for the 1-week condition is the patient's greatest pVL. For the 2-4 week criteria, data is grouped into 2-4 week blocks. The minimum value within each block is determined, and then the maximum of the minimum values is the calculated restart criteria. Each block begins with a real data value and encompasses 2-4 weeks. If no pVL value is at the end of the block, the next data point is used to complete the block. E.g. For the 2 week grouping for participant 2, the first block begins with week 1 (pVL = 1,000) and because there is no data in week 2, the value from week 3 (pVL = 2,000) is used instead. The calculated 1-, 2-, 3-, and 4-week VL cutoffs for these participants would be: Participant 1 – 800, 400, 400, 300; Participant 2 – 5,000, 1,000, 1,000, 400; Participant 3 – 15,000, 5,000, 5,000, 5,000; Participant 4 – 15,000, 3,000, 3,000, 2,000.